Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-01-19 Director's Dealing
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
董事、高级管理人员减持股份计划公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding a plan for directors and senior management to reduce their shareholdings in the company. It details the shareholders involved, the number and proportion of shares to be sold, the method and timing of the sale, and compliance with relevant securities regulations. There are no financial statements, earnings data, or report attachments. The content focuses on insider share transactions by company directors and executives. Therefore, this document fits the category of Director's Dealing (DIRS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2022-01-19 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is titled as an announcement regarding abnormal stock trading fluctuations for Jiangsu Senxuan Pharmaceutical Co., Ltd. It discusses specific recent stock price movements, the company's investigation into the causes, and confirms no undisclosed material information affecting stock price. It also states that no insiders traded shares during the period. The document is short (1982 characters) and focuses on stock price behavior and regulatory compliance disclosures rather than financial results or management reports. There is no financial data or detailed report content. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about stock trading behavior and compliance, not a full financial report or earnings release.
2022-01-13 Chinese
独立董事关于第三届董事会第十三次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion regarding a board meeting held on December 30, 2021, about anticipated related party transactions for 2022. It discusses the legality and fairness of the board meeting procedures and the related party transactions. There is no financial data, no report attached or referenced as published, and no mention of annual or interim reports. The document is a regulatory announcement related to board meeting matters and compliance, not a full report or financial statement. It fits best under Regulatory Filings (RNS) as it is a compliance-related announcement without substantive financial data or report content.
2022-01-03 Chinese
第三届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results on a specific proposal related to anticipated related-party transactions for 2022. It is not a full financial report, audit report, or earnings release. It is also not a regulatory filing or certification. The document is a formal announcement of a board meeting resolution, which fits best under Board/Management Information (MANG) as it relates to governance and supervisory board decisions.
2022-01-03 Chinese
关于召开2022年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2022 first extraordinary general meeting of shareholders (临时股东大会通知公告). It details the meeting date, voting methods, attendees, agenda items, and registration procedures. It does not contain financial statements or results, nor is it a transcript or presentation. It is a formal announcement about the meeting itself, not the meeting materials or results. The document length is 2613 characters, which is relatively short and consistent with a meeting notice. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-01-03 Chinese
关于预计2022年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the expected related party transactions for the year 2022. It includes detailed descriptions of the types of transactions, estimated amounts, related parties, and their financial data. It also describes the board and supervisory committee meetings where the related party transactions were reviewed and approved, including voting results and independent directors' opinions. The document is not a full financial report but rather a disclosure about expected related party transactions, which is a regulatory announcement. It does not contain comprehensive financial statements or management discussion and analysis. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about related party transactions.
2022-01-03 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.